Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome
S Ito, K Kamei, M Ogura, M Sato, T Fujimaru… - Pediatric …, 2011 - Springer
Rituximab (RTX) has a significant steroid-sparing effect in children with steroid-dependent
nephrotic syndrome (SDNS). However, patients are likely to relapse with the recovery of CD20…
nephrotic syndrome (SDNS). However, patients are likely to relapse with the recovery of CD20…
Decreased levels of inflammatory cytokines in immunoglobulin-resistant Kawasaki disease after plasma exchange
T Fujimaru, S Ito, H Masuda, S Oana, K Kamei… - Cytokine, 2014 - Elsevier
The pathogenesis of coronary artery aneurysm (CAA) formation in Kawasaki disease (KD)
remains unknown. However, inflammatory cytokines are thought to play an important role in …
remains unknown. However, inflammatory cytokines are thought to play an important role in …
Rituximab treatment combined with methylprednisolone pulse therapy and immunosuppressants for childhood steroid-resistant nephrotic syndrome
K Kamei, M Okada, M Sato, T Fujimaru, M Ogura… - Pediatric …, 2014 - Springer
Background Calcineurin inhibitors (CIs) with/without intravenous methylprednisolone pulse
therapy (MPT) constitute the standard treatment for childhood-onset, steroid-resistant …
therapy (MPT) constitute the standard treatment for childhood-onset, steroid-resistant …
Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during …
…, T Kuwabara, A Yonezawa, T Fujimaru… - International Journal of …, 2023 - Springer
The prevalence of CKD may be higher in patients with cancer than in those without due to
the addition of cancer-specific risk factors to those already present for CKD. In this review, we …
the addition of cancer-specific risk factors to those already present for CKD. In this review, we …
[HTML][HTML] Renal TNFα activates the WNK phosphorylation cascade and contributes to salt-sensitive hypertension in chronic kidney disease
…, S Mandai, H Kikuchi, N Takahashi, T Fujimaru… - Kidney International, 2020 - Elsevier
The inappropriate over-activation of the with-no-lysine kinase (WNK)–STE20/SPS1–related
proline/alanine-rich kinase (SPAK)–sodium chloride cotransporter (NCC) phosphorylation …
proline/alanine-rich kinase (SPAK)–sodium chloride cotransporter (NCC) phosphorylation …
Association between chronic kidney disease and mortality in stage IV cancer
T Ishii, T Fujimaru, E Nakano, O Takahashi… - International Journal of …, 2020 - Springer
Background Chronic kidney disease (CKD) is known to be associated with cancer mortality.
However, no study has considered the well-known cancer prognostic factors, ECOG …
However, no study has considered the well-known cancer prognostic factors, ECOG …
Public support for patients with intractable diseases in Japan: impact on clinical indicators from nationwide registries in patients with autosomal dominant polycystic …
…, K Katayama, W Shimabukuro, T Fujimaru… - Clinical and …, 2023 - Springer
Background Clinical practice guidelines recommend antihypertensive and tolvaptan
therapies for patients with autosomal dominant polycystic kidney disease (ADPKD) in Japan. …
therapies for patients with autosomal dominant polycystic kidney disease (ADPKD) in Japan. …
[HTML][HTML] Genetic background and clinicopathologic features of adult-onset nephronophthisis
T Fujimaru, K Kawanishi, T Mori, E Mishima… - Kidney international …, 2021 - Elsevier
Introduction Recently, nephronophthisis (NPH) has been considered a monogenic cause of
end-stage renal disease (ESRD) in adults. However, adult-onset NPH is difficult to …
end-stage renal disease (ESRD) in adults. However, adult-onset NPH is difficult to …
[HTML][HTML] Genetics may predict effectiveness of tolvaptan in autosomal dominant polycystic kidney disease
A Sekine, J Hoshino, T Fujimaru, T Suwabe… - American Journal of …, 2020 - karger.com
Background: Tolvaptan is the only therapeutic drug for autosomal dominant polycystic kidney
disease (ADPKD). The influence of mutations in polycystic kidney disease 1 and 2 genes (…
disease (ADPKD). The influence of mutations in polycystic kidney disease 1 and 2 genes (…
Metformin increases urinary sodium excretion by reducing phosphorylation of the sodium-chloride cotransporter
…, K Isobe, H Kikuchi, K Yamamoto, T Fujimaru… - Metabolism, 2018 - Elsevier
Objective Metformin is an antidiabetic drug that is widely used to treat patients with diabetes
mellitus. Recent studies have reported that treatment with metformin not only improved …
mellitus. Recent studies have reported that treatment with metformin not only improved …